P15056 (BRAF_HUMAN) Homo sapiens (Human)
Serine/threonine-protein kinase B-raf UniProtKBInterProSTRINGInteractive Modelling
766 aa; Sequence (Fasta) ;
2 identical sequences: Pan troglodytes: A0A2I3TK00; Pan paniscus: A0A2R9BBV0
Available Structures
117 Experimental Structures
| Description | PDB ID | Oligo-state | Range | Seq id (%) | Ligands | |
|---|---|---|---|---|---|---|
| Cryo-EM structure of a RAS/RAF complex (state 2) |
Heteromer P01116; Q02750; V9P4T4; | 100.0 | 2×AGS; 2×ZN; 2×MG; 1×LCJ; 1×GNP; | |||
| Cryo-EM structure of a RAS/RAF complex (state 1) |
Heteromer P01116; Q02750; V9P4T4; | 100.0 | 2×AGS; 2×ZN; 2×MG; 1×LCJ; 1×GNP; | |||
| Autoinhibited BRAF:(14-3-3)2:MEK complex with the BRAF RBD resolved |
Heteromer P63104; Q02750; | 100.0 | 2×ZN; 1×CHU; | |||
| Autoinhibited BRAF:(14-3-3)2 complex with the BRAF RBD resolved |
Heteromer P63104; | 100.0 | 2×ZN; | |||
| Structure of a MAPK pathway complex |
Heteromer Q02750; V9P4T4; | 100.0 | 1×AGS; 2×ZN; 1×ADP; 1×MG; 1×LCJ; | |||
| B-Raf:14-3-3 complex |
Heteromer A0A068JLL8; | 100.0 | ||||
| Structure of a MAPK pathway complex |
Heteromer P63104; | 100.0 | ||||
| BRAF dimer bound to 14-3-3 |
Heteromer P63104; | 94.91 | 2×29L; | |||
| Apo BRAF dimer bound to 14-3-3 |
Heteromer P63104; | 94.93 | 1×EDO; | |||
| Structure of a MAPK pathway complex |
Heteromer Q02750; V9P4T4; | 100.0 | 2×MG; 2×LCJ; 2×AGS; | |||
| Dimeric (BRAF)2:(14-3-3)2 complex bound to SB590885 Inhibitor |
Heteromer P63104; | 100.0 | 2×215; | |||
| Structure of a MAPK pathway complex |
Heteromer Q02750; V9P4T4; | 100.0 | 1×MG; 1×LCJ; 1×AGS; | |||
| Crystal structure of the BRAF:MEK1 kinases in complex with AMPPNP and PD0325901 |
Heteromer Q02750; | 100 | 2×ANP; 2×MG; 1×CL; 1×4BM; 2×SO4; 2×GOL; | |||
| Crystal structure of BRAF:MEK1 complex |
Heteromer Q02750; | 100 | 2×ANP; 2×MG; 2×CL; 1×LCJ; 1×SO4; 2×GOL; | |||
| Crystal structure of the BRAF:MEK1 kinases in complex with AMPPNP |
Heteromer Q02750; | 100 | 2×ANP; 2×MG; | |||
| Crystal structure of the BRAF:MEK1 kinases in complex with AMPPNP and Trametinib |
Heteromer Q02750; | 100 | 2×ANP; 2×MG; 1×SO4; 1×QOM; | |||
| Crystal structure of BRAF/MEK complex with NST-628 and inactive RAF |
Heteromer Q02750; | 100 | 2×ANP; 2×MG; 1×A1AHE; | |||
| Crystal structure of the BRAF:MEK1 complex |
Heteromer Q02750; | 100.0 | 2×ACP; 2×MG; 2×573; | |||
| Crystal structure of the BRAF:MEK1 kinases in complex with AMPPNP and Binimetinib |
Heteromer Q02750; | 100 | 2×ANP; 2×MG; 1×QO7; | |||
| Crystal structure of the BRAF:MEK1 kinases in complex with AMPPNP and Pimasertib |
Heteromer Q02750; | 100 | 2×ANP; 2×MG; 1×QOA; | |||
| Crystal structure of the BRAF:MEK1 kinases in complex with AMPPNP and Cobimetinib |
Heteromer Q02750; | 100 | 2×ANP; 2×MG; 1×EUI; | |||
| Crystal structure of the BRAF:MEK1 kinases in complex with AMPPNP and Selumetinib |
Heteromer Q02750; | 100 | 1×3EW; 2×ANP; 2×MG; | |||
| Crystal structure of BRAF/MEK1 complex with NST-628 and an active RAF dimer |
Heteromer Q02750; | 100.0 | 3×ANP; 1×TRS; 11×EDO; 2×A1AHE; 2×MG; | |||
| Crystal structure of the BRAF:MEK1 kinases in complex with AMPPNP and CH5126766 |
Heteromer Q02750; | 100 | 2×ANP; 2×MG; 1×SO4; 1×CHU; | |||
| BRAF-MEK complex with AMP-PCP bound to BRAF |
Heteromer Q02750; | 100.0 | 2×ACP; 2×MG; 1×SO4; | |||
| CryoEM structure of HSP90-CDC37-BRAF(V600E) complex. |
Heteromer P08238; Q16543; | 100.0 | 2×ATP; | |||
| CryoEM structure of HSP90-CDC37-BRAF(V600E)-PP5(closed) complex |
Heteromer P08238; P53041; Q16543; | 100.0 | 2×ATP; | |||
| CryoEM structure of HSP90-CDC37-BRAF(V600E)-PP5(open) complex |
Heteromer P08238; P53041; Q16543; | 100.0 | 2×ATP; | |||
| Crystal structure of bRaf in complex with inhibitor GNE-0749 | homo-4-mer | 94.28 | 4×VQP; 2×CL; | |||
| BRAF in complex with an organic inhibitor 7898734 | homo-2-mer | 100.0 | 2×734; | |||
| The complex of wild type B-RAF and BAY439006. | homo-2-mer | 99.62 | 2×BAX; 1×CL; | |||
| Crystal structure of BRAF kinase domain bound to the inhibitor 2l | homo-2-mer | 94.47 | 2×KZP; | |||
| B-Raf Kinase Domain in Complex with an Aminothienopyrimidine-based Inhibitor | homo-2-mer | 100.0 | 2×RI8; | |||
| B-Raf Kinase Domain in Complex with an Aminopyridimine-based Inhibitor | homo-2-mer | 99.62 | 2×RI9; | |||
| The complex of mutant V599E B-RAF and BAY439006. | homo-2-mer | 99.62 | 2×BAX; | |||
| Human B-Raf Kinase Domain in Complex with an Imidazopyridine-based Inhibitor | homo-2-mer | 100.0 | 2×DFS; | |||
| Crystal Structure of Human B-raf bound to a DFG-out Inhibitor TAK-632 | homo-2-mer | 100.0 | 2×1SU; | |||
| Crystal Structure of Human Kinase Domain of B-raf with a DFG-out Inhibitor | homo-2-mer | 100.0 | 2×0T2; | |||
| Crystal structure of BRAF kinase domain bound to the PROTAC P4B | homo-2-mer | 94.09 | 2×QH1; | |||
| Crystal Structure of Human B-raf bound to a DFG-out Inhibitor 5B | homo-2-mer | 100.0 | 2×1SW; | |||
| BRAF kinase in complex with TAK580 (tovorafenib) | homo-2-mer | 93.92 | 2×QOP; | |||
| Crystal structure of BRAF V600E in complex with a hybrid compound 6 | homo-2-mer | 94.53 | 19×EDO; 1×NO3; 2×TXV; | |||
| Crystal structure of BRAF in complex with a hybrid compound 6 | homo-2-mer | 94.87 | 17×EDO; 3×BR; 2×TXV; | |||
| The co-crystal structure of BRAF(V600E) with ponatinib | homo-2-mer | 94.25 | 2×0LI; 16×SO4; 2×NH4; 4×EDO; | |||
| BRAFV600E Kinase Domain In Complex with Chemically Linked Vemurafenib Inhibitor VEM-3-VEM | homo-2-mer | 94.28 | 4×DMS; 2×BEN; 3×EOH; 1×6NB; 2×CL; 1×GOL; | |||
| BRAF Kinase domain b3aC loop deletion mutant in complex with AZ628 | homo-2-mer | 100 | 2×B1E; 2×PEG; | |||
| B-Raf Kinase V600E Oncogenic Mutant in Complex with PLX3203 | homo-2-mer | 95.22 | 1×325; | |||
| BRAF kinase in complex with LXH254 (naporafenib) | homo-2-mer | 94.9 | 2×K81; | |||
| B-Raf kinase domain in complex with a tetrahydronaphthalene inhibitor | homo-2-mer | 100.0 | 2×0NF; | |||
| Crystal Structure of the Kinase domain of Human B-raf with a [1,3]thiazolo[5,4-b]pyridine derivative | homo-2-mer | 100.0 | 2×0JA; | |||
| Crystal structure of BRAF (R509H) kinase domain bound to AZ628 | homo-2-mer | 94.42 | 2×B1E; | |||
| BRAFV600E Kinase Domain In Complex with Chemically Linked Vemurafenib Inhibitor VEM-6-VEM | homo-2-mer | 94.94 | 2×6N9; 2×DMS; 1×GOL; 2×TMA; | |||
| The co-crystal structure of BRAF(V600E) with PHI1 | homo-2-mer | 94.53 | 2×E7M; 1×NHE; | |||
| Crystal structure of BRAF kinase domain bound to GDC0879 | homo-2-mer | 100.0 | 2×29L; 2×CL; | |||
| B-Raf wild-type kinase domain in complex with a purinylpyridinylamino-based inhibitor | homo-2-mer | 100.0 | 2×5XJ; | |||
| Crystal Structure of BRAF kinase domain bound to Belvarafenib | homo-2-mer | 94.48 | 2×V1Y; 12×CL; | |||
| B-Raf V600E structure bound to a new inhibitor | homo-2-mer | 94.9 | 2×5I4; | |||
| Crystal structure of bRaf in complex with inhibitor | homo-2-mer | 94.57 | 2×V5J; 1×IOD; | |||
| BRAFV600E Kinase Domain In Complex with Chemically Linked Vemurafenib Inhibitor VEM-BISAMIDE | homo-2-mer | 94.86 | 2×BEN; 1×6NC; | |||
| Crystal structure of BRAF-V600E bound to GDC0879 | homo-2-mer | 99.61 | 2×29L; 1×CL; | |||
| B-Raf Kinase domain in complex with PLX5568 | homo-2-mer | 96.31 | 2×1OO; 2×SO4; | |||
| B-Raf Kinase V600E oncogenic mutant in complex with Dabrafenib | homo-2-mer | 96.55 | 2×P06; | |||
| B-Raf Kinase V600E oncogenic mutant in complex with PLX7922 | homo-2-mer | 96.55 | 1×P02; | |||
| B-Raf Kinase V600E oncogenic mutant in complex with PLX7904 | homo-2-mer | 96.49 | 1×904; | |||
| Crystal structure of the RBD domain of serine/threonine-protein kinase B-raf from Homo sapiens. Nor… | homo-2-mer | 100.0 | ||||
| Crystal structure of the BRS domain of BRAF in complex with the CC-SAM domain of KSR1 | homo-2-mer | 100.0 | 2×GOL; | |||
| BRAF in complex with N-(4-methyl-3-(1-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-5-yl)phenyl)-3-(… | monomer | 100.0 | 1×K7S; | |||
| Pyrazole-based inhibitors of B-Raf kinase | monomer | 100.0 | 1×SM5; | |||
| Crystal Structure of Human B-Raf Kinase Domain in Complex with a Non-Oxime Furopyridine Inhibitor | monomer | 100.0 | 1×FP3; | |||
| Human B-Raf Kinase in Complex with a Non-Oxime Furopyridine Inhibitor | monomer | 100.0 | 1×FNI; | |||
| Human B-Raf Kinase in Complex with an Amide Linked Pyrazolopyridine Inhibitor | monomer | 100.0 | 1×BR2; | |||
| Crystal Structure of Wild Type BRAF kinase domain in complex with organometallic inhibitor CNS292 | monomer | 100.0 | 1×RSW; | |||
| Human B-Raf Kinase Domain in Complex with a Methoxypyrazolopyridinyl Benzamide Inhibitor | monomer | 100.0 | 1×B0R; | |||
| Human B-Raf Kinase Domain in Complex with an Bromopyridine Benzamide Inhibitor | monomer | 100.0 | 1×TV4; | |||
| Furo[2,3-c]pyridine-based Indanone Oximes as Potent and Selective B-Raf Inhibitors | monomer | 100.0 | 1×SM6; | |||
| Human B-Raf Kinase Domain bound to a Type II Pyrazolopyridine Inhibitor | monomer | 100.0 | 1×0WP; | |||
| Crystal Structure of Human B-Raf Kinase in Complex with a Non-Oxime Furopyridine Inhibitor | monomer | 100.0 | 1×FP4; | |||
| Non-oxime pyrazole based inhibitors of B-Raf kinase | monomer | 100.0 | 1×SM7; | |||
| Human B-Raf Kinase in Complex with a Furopyridine Inhibitor | monomer | 100.0 | 1×FOI; | |||
| BRAF in Complex with N-(3-(tert-butyl)phenyl)-4-methyl-3-(6-morpholinopyrimidin-4-yl)benzamide | monomer | 100.0 | 1×92D; | |||
| B-Raf Kinase in Complex with Birb796 | monomer | 94.21 | 1×B96; | |||
| BRAF in complex with compound 3 | monomer | 100.0 | 1×10Z; | |||
| Crystal structure of BRAF kinase domain with PF-07284890 | monomer | 98.9 | 1×PEG; 1×GOL; 1×A1AN9; | |||
| Crystal structure of RAF kinase domain bound to the inhibitor 2a | monomer | 94.38 | 1×EU4; | |||
| B-Raf Kinase in Complex with PLX4720 | monomer | 94.55 | 1×324; | |||
| Crystal structure of a BRAF kinase domain monomer | monomer | 95.11 | 1×324; | |||
| Structure of BRAF in Complex With Exarafenib (KIN-2787). | monomer | 100.0 | 1×WJ9; 3×CL; | |||
| BRAF Kinase domain b3aC loop deletion mutant in complex with dabrafenib | monomer | 100 | 1×P06; | |||
| B-Raf V600E Kinase Domain Bound to a Type II Dihydroquinazoline Inhibitor | monomer | 99.62 | 1×B1E; | |||
| Highly Potent and Selective 3-N-methylquinazoline-4(3H)-one Based Inhibitors of B-RafV600E Kinase | monomer | 100.0 | 1×2VX; | |||
| Crystal Structure of B-Raf Kinase Domain in Complex with a Dihydropyrido[2,3-d]pyrimidinone-based I… | monomer | 100.0 | 1×T1Q; | |||
| BRAF in Complex with RAF709 | monomer | 100.0 | 1×92J; | |||
| BRAF in complex with N-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluo… | monomer | 100.0 | 1×K81; | |||
| CRYSTAL STRUCTURE OF B-RAF IN COMPLEX WITH BI 882370 | monomer | 95.02 | 1×54J; 1×GLC; | |||
| BRAF Kinase domain b3aC loop deletion mutant in complex with sorafenib | monomer | 100 | 1×BAX; | |||
| B-RAF in complex with Dabrafenib | monomer | 94.49 | 1×P06; | |||
| The Complex of wild-type B-RAF with Pyrazolo pyrimidine inhibitor | monomer | 100.0 | 1×831; 2×PO4; | |||
| Crystal structure of the BRAF (R509H) kinase domain monomer bound to Vemurafenib | monomer | 94.25 | 1×032; | |||
| Crystal structure of BRAF V600E oncogenic mutant in complex with TAK-580 | monomer | 94.88 | 1×QOP; | |||
| BRAF in Complex with RAF265 | monomer | 100.0 | 1×55J; | |||
| Crystal structure of the insect cell-expressed WT-BRAF kinase in complex with Dabrafenib | monomer | 100.0 | 1×P06; 1×CL; | |||
| B-Raf Kinase V600E mutant in complex with a diarylthiazole B-Raf Inhibitor | monomer | 94.8 | 1×CQE; | |||
| B-Raf Kinase V600E oncogenic mutant in complex with PLX4032 | monomer | 94.33 | 1×032; | |||
| Crystals Structure of B-Raf kinase domain in complex with an Imidazopyridinyl benzamide inhibitor | monomer | 100.0 | 1×8EN; | |||
| B-Raf V600E kinase domain in complex with an aminoisoquinoline inhibitor | monomer | 100.0 | 1×L1E; | |||
| CRYSTAL STRUCTURE OF BRAF(V600E) IN COMPLEX WITH LY3009120 COMPND | monomer | 100.0 | 1×4Z5; | |||
| Structure of the B-Raf kinase domain bound to SB-590885 | monomer | 100.0 | 1×215; | |||
| The complex structure of Braf V600E kinase domain with a novel Braf inhibitor | monomer | 94.47 | 1×3K3; | |||
| Crystal Structure of BRAF Kinase Domain Bound to AZ-VEM | monomer | 95.2 | 1×6DC; | |||
| bRaf complexed with an inhibitor | monomer | 98.05 | 1×GOL; 1×4EF; | |||
| Solution NMR Structure of the Ras-binding domain of Serine/threonine-protein kinase B-raf from Homo… | monomer | 100 | ||||
| Solution structure of Ras Binding Domain (RBD) of B-Raf | monomer | 100 | 1×6FS; | |||
| Solution structure of Ras Binding Domain (RBD) of B-Raf complexed with Rigosertib (Complex I) | monomer | 100 | 1×6FS; | |||
| Solution structure of Ras Binding Domain (RBD) of B-Raf | monomer | 100 | ||||
| Crystal structure of the BRS domain of BRAF | monomer | 100.0 | 1×SO4; | |||
| CRAF ras-binding domain chimera, ligand complex | monomer | 100 | 1×USX; | |||
| CRAF ras-binding domain chimera, apo form | monomer | 100 | ||||
3 SWISS-MODEL models
| Template | Oligo-state | QMEAN | Range | Ligands | Trg-Tpl Seq id (%) | |
|---|---|---|---|---|---|---|
| 8dgt.1.A | monomer | 0.64 | 2×ZN; | 100.00 | ||
| 8dgs.1.A | monomer | 0.60 | 1×AGS; 2×ZN; | 100.00 | ||
| 7z37.1.C | monomer | 0.54 | 62.35 | |||